Wordt geladen...
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
The development of cyclin-dependent kinase (CDK) 4/6 inhibitors has been more prominent in hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancers, with a significant improvement in progression-free survival (PFS) in first and later lines of metastatic...
Bewaard in:
| Gepubliceerd in: | Ther Adv Med Oncol |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
SAGE Publications
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6299331/ https://ncbi.nlm.nih.gov/pubmed/30619511 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918818346 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|